GGDPS inhibitors for the treatment of cancer
New drugs help treat multiple myeloma and other types of cancer by targeting a protein called geranylgeranyl diphosphate synthase, also known as GGDPS. GGDPS is involved in the regulation of the Rab family of small but important proteins that are also often linked to cancer: GTPases. Targeting GGDPS may provide a way to inhibit Rab family proteins, providing a unique way to treat various forms of cancer.
Developed by a collaboration of researchers at the University of Nebraska Medical Center and the University of Iowa, the new GGDPS inhibitors have nanomolar potency and significantly reduced tumor volume in a multiple myeloma model. The compounds are also currently being assessed in vivo to determine pharmacokinetic properties.